Sec. 37. 21-A MRSA §191, as amended by PL 2005, c. 364, §6 and c. 453, §40, is further amended by adding a new paragraph before the last paragraph to read:

For the purposes of generating an incoming voting list, the central voter registration system must be capable of being sorted so that the Address Confidentiality Program voter codes and the address assigned each voter by the program appear at the end of the alphabetized list and are printed on a separate page of the list.

Sec. 38. 22 MRSA §661, as amended by PL 2005, c. 254, Pt. B, §2, is further amended to read:

§661. Public policy

In the interests of the public health and welfare of the people of this State, it is the declared public policy of this State that a facility licensed by the United States Nuclear Regulatory Commission and situated in the State must be accomplished in a manner consistent with protection of the public health and safety and in compliance with the environmental protection policies of this State. It is the purpose of this chapter, in conjunction with sections 671 to 690; Title 25, sections 51 and 52; and Title 35-A, sections 4331 4351 to 4393, to exercise the jurisdiction of the State to the maximum extent permitted by the United States Constitution and federal law. Nothing in this chapter may be construed as an attempt by the State to regulate radiological health and safety reserved to the Federal Government by reason of the United States Atomic Energy Act of 1954, as amended.

Sec. 39. 22 MRSA §2700-A, sub-§4, as enacted by PL 2005, c. 392, §1, is amended to read:

4. Fees. Beginning April 1, 2006, each manufacturer of prescription drugs that are provided to Maine residents through the MaineCare program under section 3174-G or the elderly low- cost drug program under section 254 254-D shall pay a fee of $1,000 per calendar year to the department. Fees collected under this subsection must be used to cover the cost of overseeing implementation of this section, including but not limited to maintaining links to publicly accessible websites to which manufacturers are posting clinical trial information under subsection 3 and other relevant sites, assessing whether and the extent to which Maine residents have been harmed by the use of a